Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Simone Garcovich, Clara De Simone, Emilio Berti & Angelo Valerio Marzano. (2017) Drug management of neutrophilic dermatoses. Expert Review of Clinical Pharmacology 10:10, pages 1119-1128.
Read now
Read now
Articles from other publishers (14)
Yuanyuan Xu, Zhixuan Li, Shuwei Wu, Linghong Guo & Xian Jiang. (2023) Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis. Frontiers in Immunology 14.
Crossref
Crossref
Sydney Thai, Sophie Barlow, James Lucas, James Piercy, Yichen Zhong, Joe Zhuo & Jashin J. Wu. (2023) Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey. Dermatology and Therapy 13:6, pages 1289-1303.
Crossref
Crossref
George Martin. (2023) Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors. Dermatology and Therapy 13:2, pages 417-435.
Crossref
Crossref
Suxing Liu, Di Li & Weikang Tao. 2022. Psoriasis - New Research. Psoriasis - New Research.
Matteo Megna, Luca Potestio, Nicola Di Caprio, Andrea Tajani, Gabriella Fabbrocini & Alberto Annunziata. (2022) Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?. Dermatologic Therapy 35:5.
Crossref
Crossref
Matteo Megna, Sonia Sofìa Ocampo‐Garza, Gabriella Fabbrocini, Eleonora Cinelli, Angelo Ruggiero & Elisa Camela. (2021) A case of erythrodermic psoriasis successfully treated with apremilast. Dermatologic Therapy 35:1.
Crossref
Crossref
James G. Krueger, Iain B. McInnes & Andrew Blauvelt. (2022) Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. Journal of the American Academy of Dermatology 86:1, pages 148-157.
Crossref
Crossref
Elisa Camela, Sonia Sofía Ocampo‐Garza, Eleonora Cinelli, Alessia Villani, Gabriella Fabbrocini & Matteo Megna. (2021) Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. Dermatologic Therapy 34:2.
Crossref
Crossref
Lori S. Kim, Jashin J. Wu & George Han. (2021) Deucravacitinib for Psoriasis. Current Dermatology Reports 10:1, pages 1-5.
Crossref
Crossref
Vignesh Ramachandran, Ted Rosen, Misha Koshelev & Fareesa Shuja Sandoval. 2021. Advances in Psoriasis. Advances in Psoriasis
119
140
.
Miguel Nogueira, Luis Puig & Tiago Torres. (2020) JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs 80:4, pages 341-352.
Crossref
Crossref
Viktor Todorović, Zhi Su, C. Brent Putman, Stevan J. Kakavas, Katherine M. Salte, Heath A. McDonald, Joseph B. Wetter, Stephanie E. Paulsboe, Qi Sun, Clare E. Gerstein, Limary Medina, Bernhard Sielaff, Ramkrishna Sadhukhan, Henning Stockmann, Paul L. Richardson, Wei Qiu, Maria A. Argiriadi, Rodger F. Henry, J. Martin Herold, J. Brad Shotwell, Steve P. McGaraughty, Prisca Honore, Sujatha M. Gopalakrishnan, Chaohong C. Sun & Victoria E. Scott. (2019) Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis. Scientific Reports 9:1.
Crossref
Crossref
Giulia Radi, Annamaria Campanati, Federico Diotallevi, Elisa Molinelli & Anna Offidani. (2019) Skin involvement in patients with psoriatic arthritis: preliminary results of treatment with apremilast in real world setting. Giornale Italiano di Dermatologia e Venereologia 154:2.
Crossref
Crossref
Caleb Jeon, Mio Nakamura, Sahil Sekhon, Di Yan, Jashin J. Wu, Wilson Liao & Tina Bhutani. (2017) Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities. JAAD Case Reports 3:6, pages 495-497.
Crossref
Crossref